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ABSTRACT
IN THE SURGICAL PATIENT REQUIRING NEUROMUSCULAR BLOCKADE, IS
THERE AN INCREASED INCIDENCE OF POSTOPERATIVE ADVERSE
RESPIRATORY EVENTS WITH ROCURONIUM OR VECURONIUM?
by Martha Claudine Boos
December 2015
It is estimated that up to 45% of surgical patients will have postoperative residual
neuromuscular blockade (NMB) upon arrival to the postanesthesia care unit (PACU), and
incomplete recovery can impair upper airway function and contribute to adverse
respiratory events (Nagelhout & Plaus, 2014). This retrospective cohort study examined
whether there was an increased incidence of postoperative adverse respiratory events
with the neuromuscular blocking agents Rocuronium or Vecuronium. Inclusion criteria
included any surgical patient aged 18-65, receiving NMB agents Rocuronium or
Vecuronium during the procedure. Exclusion criteria included any surgical patient aged
18-65 with ASA classification > 4, any emergent cases, any patient with documented
neuromuscular disorder or history of prolonged intubation, and patients arriving intubated
preoperatively. A Pearson Chi-Square test statistic was used to evaluate whether the
patients receiving Rocuronium experienced a greater increase in post-operative adverse
respiratory events compared with the patients whom received Vecuronium.
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CHAPTER I
INTRODUCTION
Statement of the Problem
General anesthesia is the act of rendering a patient unconscious and
unresponsive to painful stimuli, and in some general anesthesia cases, the usage of
a NMB is also required. Their action is to block acetylcholine from activating
nicotinic receptors on skeletal muscles, and acetylcholine is the neurotransmitter
responsible for muscle contraction (Guyton & Hall, 2011). Therefore, NMB
agents produce muscle relaxation that facilitate tracheal intubation and optimize
the surgical field. However, with the use of these agents, residual neuromuscular
blockade can occur which can impair upper airway function contributing to
adverse respiratory events in the postanesthesia care unit (PACU). Given that
postoperative NMB is a potentially preventable incident, it is important to find
ways to prevent this patient safety problem from occurring.
Clinical Question
In the surgical patient requiring neuromuscular blockage, is there an
increased incidence of adverse respiratory events with the usage of the
intermediate acting agent Rocuronium or Vecuronium? Confounding variables
such as length of procedure, age, gender, comorbidities, dosages of
neuromuscular blocking agent administered, train-of-four (TOF) testing,
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inhalation agent utilized, and if a reversal agent was administered, were
examined.
Problem Statement
Each year approximately 74 million individuals will undergo surgery, and
of these, approximately 60% will receive general anesthesia and some form of a
neuromuscular blockade agent (Advisory Board Company, 2014; CDC, 2014). It
is estimated that up to 45% of patients will have postoperative residual
neuromuscular blockade upon arrival to the postanesthesia care unit (Nagelhout &
Plaus, 2014). This incomplete recovery of neuromuscular function can impair
upper airway function and contribute to adverse respiratory events. In the United
States, up to 3% of these patients with residual neuromuscular blockade will
experience clinically evident events such as serious respiratory complications, and
these events are associated with increase in morbidity and mortality (Nagelhout,
2013). Furthermore, according to the Agency for Healthcare Research and
Quality (AHRQ), these adverse events and other adverse medical events cost the
United States in excess of 19.5 billion dollars annually (AHRQ, 2011).
Purpose of the Project
The purpose of this capstone project was to determine if surgical patients
receiving Rocuronium or Vecuronium are at a greater risk of experiencing an
adverse respiratory event. Variables, such as length of procedure, age, gender,
comorbidities, dosages of neuromuscular blocking agent administered, train-of-
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four (TOF) testing, and if a reversal agent was administered, were all addressed.
Results were disseminated, and a white paper change proposal was shared with
the identified key stakeholders in an effort to reduce future incidence of adverse
respiratory events associated with residual neuromuscular blockade in the
postoperative patient.
Conceptual and Theoretical Framework
Integrating nursing theory into practice provides the foundation for which
nurses pursue understanding of patients and their health concerns. Therefore, the
purpose of nursing theories is to guide the care and improve patient outcomes. In
exploring the many nursing theories that could apply to this capstone project, the
Neuman’s systems model theory was identified. The Neuman’s systems theory is
a systems-based guide that focuses on person, environment, health, and nursing
(Whetsell, Gonzalez, & Moreno-Fergusson, 2011). The theory involves patient
processes and outcomes, and is based on the client’s perception, reaction, and
resolution to stress. The three main concepts of Neuman’s systems theory include
stress, homeostasis, and patient perception. The theory is based on wholism, with
a focus on stress and systematic feedback loops, and takes into account all the
variables that can affect a patient’s response to stress (Neuman, 1995).
Furthermore, “Neuman considered all variables affecting a client’s response to
environmental stressors and explains that knowing something about one part of a
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system enables us to know something about another part” (Whetsell et al., 2011,
p. 431).
The Neuman’s model focused on three types of prevention that help
promote wellness. The three types of prevention include primary, secondary, and
tertiary. According to Zaccagnini and White (2014), primary prevention involves
identifying stressors before the patient encounters the stressor; secondary
prevention involves assisting the patient to overcome the stressor once it has
occurred; and tertiary prevention involves focusing on maintaining wellness after
the patient has encountered a stressor. Lastly, the Neuman’s systems theory
envelops a total person approach by evaluating the environment and
understanding how the environment affects the patient.
In the field of anesthesia, the Neuman’s systems theory can be applied in
several aspects of nursing care. The bulk of interventions carried out by the
anesthesia providers are aimed at decreasing physical and emotional stress. As
stated before, the Neuman’s theory focuses on stress and the variables that affect
the client’s response to that stress. Therefore, in preforming a pre-anesthetic
evaluation, factors that can influence the perceptions of the client can be
identified. These factors, or variables, can be taken into account while developing
an anesthetic plan for that patient. Striving to maintain the normal line of defense
by blocking those identified stressors can help the anesthesia provider maintain a
homeostatic environment for the patient. From the initial preoperative evaluation,
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through the administration of agents such as anxiolytics, vagolytics, and
anesthetics, to the postoperative examination, these actions can be performed in
an attempt to maintain homeostasis (Martin, 1996). All of these actions or
interventions are aspects of applying Neuman’s systems theory into the advanced
nursing practice of anesthesia.
The area of interest for this study involved comparing the incidence of
postoperative adverse respiratory events in patients receiving Rocuronium versus
Vecuronium for neuromuscular blockage during surgery. Adverse respiratory
events can include hypoxia, delayed extubation, or a patient requiring reintubation
after a surgical procedure. For this capstone, a retrospective analysis was
performed. Variables such as gender, age, American Society of Anesthesiologists
(ASA) classification, type of surgery, length of surgery, number of doses of each
medication (total dose administered), reversal (full, partial, or none), train-of-four
documentation, temperature, body mass index (BMI), comorbidities, reintubation
rate percentage for each NMB agent, length in PACU, inhalation agent used, and
disposition (discharged home, transferred to ICU, expired) were identified and
analyzed to consider their affects upon systems. Furthermore, this capstone
utilized the Neuman’s theory by evaluating the anesthetic process and outcomes
of the patients included within the analysis of data.
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Needs Assessment
Thousands of surgeries are performed every day in the U.S., with the
majority of these being done as ambulatory procedures. Advances in medical
technology and improvements in anesthesia now allow patients to regain
consciousness quicker and return home faster without complications. While most
patients will not experience an adverse event, a few will experience
complications.
Several preexisting factors are known to increase the risk of postoperative
pulmonary complications associated with residual neuromuscular blockade.
These factors include renal impairment, liver impairment, preexisting lung disease
such as chronic obstructive pulmonary disease, asthma, or emphysema, poor
health, obesity, and smoking (Yoder & Sharma, 2011). Fluid and electrolyte
imbalances, hypothermia, drug interactions, neurological and muscular diseases,
and genetics may affect the patients’ ability to overcome the effects of residual
muscular paralysis (Wilson, Collins, & Rowan, 2012). Other factors include
advanced age and male gender. Abdominal or orthopedic surgeries and the length
of the surgery have been shown to increase the risk of residual paralysis. Finally,
the anesthetic variables that potentiate adverse effects include the usage of
neuromuscular blockage agents, opioids, and general anesthesia (Murphy et al.,
2008).
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The patient with the greatest risk of an adverse respiratory event
associated with residual neuromuscular blockade would include those with a
history of Chronic Obstructive Pulmonary Disease (COPD) and smoking. COPD
is the third leading cause of death in the United States, and 90% of the diagnoses
cases are individuals over the age of forty-five (American Lung Association,
2011). Therefore, this disease can pose a major risk for those undergoing any
procedure, especially one requiring general anesthesia.
Obesity and a history of apnea are also syndemically associated.
Increased fat deposition in the pharynx can cause compression and obstruction to
the airway tract. Therefore, if residual paralysis is allowed to occur, this can
potentially increase the risk of the patient requiring reintubation due to airway
obstruction. Finally, renal and liver impairment can prolong the effects of
neuromuscular blockade. The kidneys and/or the liver metabolize all anesthetic,
analgesic, opioid, and muscle relaxant drugs. Therefore, if a patient has liver or
renal disease, this can and will prolong the effects of all medications (Morgan,
Mikhail, & Murray, 2007). In reviewing the factors that increase the risk of
residual neuromuscular blockade, all are noted components associated with the
majority of patients whom receive care at the facility of choice.
Determining which nondepolarizing agent has a higher incidence of
residual neuromuscular blockade resulting in adverse respiratory events will be a
great strength and benefit to the identified key stakeholders at the hospital.
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However, one weakness of the project could involve anesthesia providers feeling
threatened by the review of patient data in regards to the anesthesia technique
utilized and outcome results. The opportunity of completing the outcome analysis
of the capstone will reveal and answer the question if Rocuronium is associated
with an increase in adverse respiratory events in surgical patients requiring
neuromuscular blockade during surgery. Thus results will determine possible
change in practice. A threat to the project may involve the data revealing that no
significant difference in outcomes with the usage of Rocuronium over
Vecuronium, but that the incidence may be related to other variables not within
the provider’s control.
Significance and Implications
The significance of this capstone was to determine if there is an increased
incidence of adverse respiratory events with Rocuronium versus Vecuronium. If
there is an increased incidence of adverse respiratory events with Rocuronium
over Vecuronium, then those results will be disseminated to the anesthesia
department in a white paper proposal with the aim to improve future surgical
outcomes. In addition, each variable was evaluated in an effort to determine if
practice changes should occur to improve the possibility of an adverse event. As
stated before, according to the Agency for Healthcare Research & Quality, these
adverse events and other adverse medical events cost the United States in excess
of 19.5 billion dollars annually (AHRQ, 2011). Furthermore, according to Zhang
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et al. (2009), these adverse events can extend OR time contributing to high cost
utilization.
If this capstone demonstrates to provide statistically significant
information, a pilot study could be performed. The recommendations made with
the white paper proposal could be tested to verify feasibility and accuracy of the
proposed changes. According to Gearing, Mian, Barber, and Ickowicz (2006), a
pilot study is basically a small version of a proposed research plan that can offer
researchers valuable information. If that data suggests that Rocuronium has a
greater incidence of adverse respiratory events, this information could guide the
anesthesia provider in the future in an effort to improve patient outcomes.
Review of Literature
Each year approximately 70 million individuals will undergo surgery, and
of these, approximately 60% will receive general anesthesia and some form of a
neuromuscular blockade agent (Advisory Board Company, 2014; CDC, 2014). In
fact, it is estimated that approximately 45% of postoperative patients will have
residual neuromuscular blockade upon arrival to the recovery room (Nagelhout &
Plaus, 2014). However, approximately 90% of United States anesthesia providers
and 80% of European anesthesia providers say they have never encountered this
issue (Murphy, 2012). It is believed this discrepancy is due to the providers not
recognizing the signs and symptoms of residual paralysis, and choosing to relate
the adverse events to obesity or some other probable comorbidity issue. In
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addition, 6 out of every 10 surgeries will be performed as a same-day operative
procedure, and one may think there are minimal risks associated with such
procedures. However, approximately 100,000 individuals will experience adverse
respiratory events related to residual neuromuscular blockade (Marcus, 2012).
General anesthesia is the act of producing unconsciousness and
unresponsiveness to all painful stimuli, and in some general anesthesia cases, the
usage of a muscle relaxant or neuromuscular blockade agent is also required
(Lehne, 2004). Nondepolarizing neuromuscular blocking agents are used to
prevent undesired patient movement during some surgical procedures. Their
action is to block acetylcholine, which is responsible for muscle contraction, from
activating nicotinic receptors on skeletal muscles (Guyton & Hall, 2011). NMB
produces muscle relaxation to assist the surgeon in procedures that require
complete relaxation such as in abdominal cases. However, with the use of these
agents, risks are involved if not monitored closely by the anesthesia provider.
Lastly, as stated before, several adverse effects are associated with the use of
neuromuscular blockade agents such as respiratory depression, aspiration, airway
obstruction, and muscle weakness (Wilson et al., 2012).
Residual neuromuscular blockade is not a new phenomenon. In fact, over
60 years ago, Dr. Henry Knowles Beecher and Dr. Donald Todd published a study
in the Annals of Surgery regarding this issue. Their study involved ten hospitals
and 599,548 anesthetic procedures administered between 1948 and 1952 (Beecher
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& Todd, 1954). According to their study, patients administered a neuromuscular
blockade agent had a six-fold increase in mortality than patients not administered
a neuromuscular blockade agent (Beecher & Todd, 1954). Most of the causes of
death were related to patient disease process, surgical management, anesthetic
management, and adverse respiratory events. In the 1970s, studies were
performed by Viby-Mogensen, and they concluded approximately 42% of patients
had residual paralysis upon arrival to the recovery unit (Murphy, 2012). In the
1980s, studies concluded 21% to 36% had residual from the neuromuscular
blockade agent, and in the mid 2000s, several compiled studies revealed residual
in as high as 65% of the patients (Murphy, 2012). Many studies over the last 20
years have involved healthy subjects whom volunteered to undergo procedures
with neuromuscular blockage agents. The end results concluded that there were
two main adverse events associated with residual neuromuscular blockade. Those
adverse events included airway obstruction and extreme muscle weakness. With
this investigation, it also concluded that 33% reported upper airway obstruction,
and over half complained of the impaired ability to swallow (Murphy, 2012).
However, the relevant question is whether the problem exists in anesthesia today?
Currently, as many as 100,000 patients experience some form of an
adverse respiratory event after surgery linked to residual neuromuscular blockade
agents. This accounts annually for approximately 0.8% of the patients, with 0.1%
of the patients requiring reintubation due to the residual respiratory paralysis
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(Marcus, 2012). Recently, in a study conducted by Murphy and colleagues, data
were collected over a one-year period on 7,459 patients whom received general
anesthesia. Of those, approximately 0.8% demonstrated residual neuromuscular
blockade and suffered a critical respiratory event (Murphy et al., 2008). The
study suggested that incomplete recovery from neuromuscular blockade is an
important contributing factor in postoperative adverse respiratory events.
Potential Legal Implications of an Adverse Event
According to the Agency for Healthcare Research and Quality (AHRQ),
these adverse events and other adverse medical events cost the United States in
excess of 19.5 billion dollars a year (AHRQ, 2011). However, this is not just an
U.S. issue, it occurs globally. In fact, to help decrease the incidence, the
Association of Anaesthetists of Great Britain and Ireland require nerve stimulators
be available whenever a neuromuscular blockade agent is administered during
surgery and must be available in the recovery unit (Marcus, 2012). One study
conducted in the Netherlands involved approximately 870,000 patients. The
investigation determined that poor management of neuromuscular blockade
agents was the most significant factor for death or coma. The study also
concluded that usage of reversal agents reduced the mortality rates by 90%,
compared to not using reversal agents. Lastly, a study conducted in South Africa
involving over 240,000 patients concluded that respiratory failure related to
residual paralysis was the second leading cause of death attributed to anesthesia,
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following hypovolemia which was the leading cause of death (Murphy, 2012). As
one can conclude, this is a global issue that requires further investigation and
review of standards.
A literature review conducted by MacRae (2007) involving 7,117 closed
anesthesia claims revealed lack of vigilance is believed to be the leading cause of
all adverse events. In fact, despite the fact that airway management is considered
the anesthesia provider’s area of expertise, difficultly in managing the airway is
the leading cause of morbidity and mortality for anesthesia. According to
MacRae (2007), results from the closed claims studies in anesthesia revealed that
approximately 45% of the cases were related to respiratory events, 31-32 % to
death or brain damage, 25% to a cardiovascular event, and approximately 21% to
nerve injury. Anesthesia providers must be aware that the median cost of a
malpractice suit is approximately $300,000 (Bishop, Ryan, & Cassalino, 2011).
Therefore, it is important to identify and examine preventive measures that could
decrease this incidence.
Current Recommended Prevention Measures
There are several recommended measures all anesthesia providers can
perform to potentially decrease the incidence of residual neuromuscular blockade.
On December of 2012, the Anesthesia Patient Safety Foundation (APSF)
sponsored a panel titled, “Residual Muscle Relaxant Induced Weakness in the
Postoperative Period: Is It a Patient Safety Issue?” According to Morell (2013),
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the panel of experts agreed that routine monitoring of neuromuscular blockade
should be performed routinely and a train-of-four (TOF) ratio of >0.9 is an
appropriate goal. The panel of experts concluded that lesser TOF ratios could
increase the potential for adverse events, both short-term and long-term (Morell,
2013). According to Stoelting (2014), following the APSF meeting, a survey was
conducted using random sampling of 25% of the active members (21,482), and
resulted with 90% of respondents agreeing that there is a need for routine
intraoperative monitoring of neuromuscular blockade. Furthermore, the survey
results also overwhelmingly recommended the APSF should encourage the
American Society of Anesthesiologists (ASA), American Association of Nurse
Anesthetists (AANA), and American Academy of Anesthesiologist Assistant
(AAAA) to adopt monitoring neuromuscular function as part of their standards of
care.
According to Foster and Callahan (2011), “standards are rules or
minimum requirements that describe specific responsibilities and principles of
patient care and define the expectations against which professional performance
can be measured” (p. 157). Since that time, the AANA, ASA, and AAA have
adopted such a standard or recommendation. According to the AANA Standards
for Nurse Anesthesia Practice (2013), “when neuromuscular blocking agents are
administered, monitor neuromuscular response to assess depth of blockade and
degree of recovery” (p. 2). Therefore, to adequately monitor the depth of
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blockade and degree of recovery, the anesthesia provider must utilize certain
techniques such as physical assessment and the use of a peripheral nerve
stimulator.
The peripheral nerve stimulator is a device that verifies the TOF
responses. The TOF is a series of four minimal shocks that are applied to a
peripheral nerve such as the facial nerve. The anesthesia provider will count the
number of twitches elicited from the 4 shocks. If 4 twitches are observed, this
could indicate that approximately 0-75% of the receptors are still blocked. Three
twitches indicate approximately 75% are blocked. Two twitches could mean
approximately 80% are blocked, and no twitches would indicate 100% blockage
(Saenz, 2011).
The percentage of blockage is directly related to the amount of muscle
relaxant or paralysis (Nagelhout & Plaus, 2014). The anesthesia provider will
observe for a fade. A fade is a decreasing in amplitude noted with the twitches,
and this result is directly related to the amount of paralysis present from the
neuromuscular agent. Therefore, as a primary prevention, the anesthesia provider
should utilize the TOF when monitoring the patient to determine readiness for
extubation at the end of the procedure. However, not all anesthesia providers
utilize the TOF monitoring device. In fact, it is estimated only 22% of the
practitioners in the U.S., and only 70% of the European anesthesia providers
report using this TOF device (Donati, 2010).

16
Another recommended prevention measure is routine pharmacologic
reversal of a nondepolarizing neuromuscular blockade (Miller & Ward, 2010).
After an extensive review, Miller and Ward (2010) stated their opinion as, “these
databases and our own review of many cases of adverse outcomes has led to the
conclusion that reversal of NMB with neostigmine should be routine.
Conversely, there should be written documentation as to why neostigmine was
unnecessary” (p. 2). According to the Neostigmine package insert, Neostigmine
inhibits the hydrolysis of acetylcholine by directly competing with acetylcholine
for cholinergic receptor sites, has a half life of 24 – 113 minutes, should be
administered slowly over at least one minute, and takes a minimum of 10 minutes
to achieve a TOF of 90% reversal (Eclat Pharmaceuticals, 2014). As
acetylcholine levels build, a return of muscle contraction begins thereby reversing
the effects of the NMB. According to Nagelhout (2013), the recommended
protocol is to have a minimum of 2 twitches from a TOF when neostigmine is
administered. Lastly, according to Eclat Pharmaceuticals (2014), since
Neostigmine has a direct postsynaptic cholinergic effect, these effects can be
managed by administration of glycopyrrolate or atropine in a separate syringe
prior to Neostigmine administration.
One retrospective cohort study concluded that patients whom received a
reversal agent were associated with a reduction of elapse operating room (OR) or
PACU time (Zhang, et al., 2009). The retrospective study involved reviewing
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9670 elective surgeries performed under general anesthesia and using one or more
neuromuscular blocking agents. The study concluded that utilizing a reversal
agent may lead to more efficient OR resources since the reversal agent was shown
to reduce OR time 12 to 46 minutes in the majority of the surgical cases (Zhang et
al., 2009). Brull, Kopman, and Naguib (2013), reported successful antagonism is
enhanced when the antagonist such as neostigmine is administered 15 to 20
minutes before tracheal extubation and when there is a TOF of 4 twitches.
However, routine reversal is not a common practice. In fact, only 34% of
clinicians in the United States and 18% of anesthesia providers from Europe
report routine usage (Nagelhout, 2013). In a survey conducted involving 108
clinical anesthesiologists, the decision to reverse a neuromuscular blocking agent
was based on the pharmacological knowledge of the medication and on personal
judgment of patient breathing (Videira & Vieira, 2011). According to Videira and
Vieira (2011), “clinicians judge themselves as better skilled at avoiding residual
block than they do their colleagues, making them overconfident in their capacity
to estimate the duration of action of intermediate-acting NMBD” (p. 1192).
Comparison of Rocuronium and Vecuronium
Rocuronium and Vecuronium are two nondepolarizing relaxants with
similar efficacy. Rocuronium is usually the drug of choice on induction and is
widely used when succinylcholine, a depolarizing relaxant, is contraindicated.
Rocuronium has a faster onset or 45 to 90 seconds, duration of 30 to 60 minutes,
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undergoes both hepatic and renal elimination, and has an elimination half-life of
60 to 120 minutes (Nagelhout & Plaus, 2014). In comparison, Vecuronium is also
an intermediate acting nondepolarizing agent with an onset of 3.1 minutes,
duration of 30 to 45 minutes, undergoes hepatic and renal elimination, and has an
elimination half-life of 51 to 91 minutes (Nagelhout & Plaus, 2014). In addition,
reversal of the effects of these nondepolarizing relaxants requires time or the
usage of an anticholinesterase agent.
Several studies have evaluated the incidence and duration of postoperative
residual neuromuscular blockade between Vecuronium, Rocuronium, and other
non-depolarizing muscle relaxants. One such study conducted by Khan, Divatia,
and Sareen (2006), concluded that residual neuromuscular blockade was
significantly higher with Rocuronium at 37% compared to 17% with Vecuronium.
In another study involving 60 patients, 20 received Rocuronium, 20 received
Vecuronium, and the other 20 received Cisatracurium. The results concluded that
intubation times were shorter in those receiving Rocuronium, recovery time was
faster with Cisatracurium, and TOF was significantly longer with Rocuronium
(Sagir et al., 2013). Several studies revealed patients could experience residual
paralysis for several hours after neuromuscular blockade administration.
One such study involved 526 patients whom received a single intubating
dose of Rocuronium, Vecuronium, or Atricurium and did not receive a reversal
agent. The TOF ratio was measured upon admission into the PACU, and the
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study concluded that residual paralysis is common even more than 2 hours after
administration of an intubating dose of an intermediate acting muscle relaxant
(Debaenne, Plaud, Dilly, & Donati, 2003). In a case report involving an 84 yearold female undergoing elective hysterectomy and receiving a one-time intubating
dose of Rocuronium, the study revealed that it might take more than 3.5 hours
before it is possible to antagonize a block (Claudius, Karacan, & Viby-Mogensen,
2007). Therefore, one may conclude from these studies, when deciding which
intermediate-acting non-depolarizing muscle relaxant to utilize, Vecuronium may
be the more reliable choice. However, further studies may be beneficial.
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CHAPTER II
METHODOLOGY
The purpose of this capstone project was to determine if surgical patients
receiving Rocuronium or Vecuronium are at a greater risk of experiencing an
adverse respiratory event. The methodology of this capstone will follow this
order: 1) Setting, 2) Target Outcomes, 3) Barriers, 4) Populations, 5) Sampling, 6)
Research Strategies, 7) Methods, and 8) Measurement Methods.
Setting
The capstone setting for this retrospective analysis took place at a level II
regional trauma center located in Hattiesburg, Mississippi. It is a 512-bed facility
offering services to the surrounding 19 counties, performing over 7000 inpatient
and 9900 outpatient procedures each year (Forrest General Hospital, 2014). In
2013, the hospital successfully installed the Electronic Patient Integrated Care
(EPIC) system. Therefore, this hospital provided an excellent setting to perform
the retrospective analysis.
Target Outcome
The desired goal for this capstone was to determine if surgical patients
requiring neuromuscular blocking agents are at a greater risk of experiencing an
adverse respiratory event with the intermediate acting agents Rocuronium or
Vecuronium. The desired outcome of the project was to develop a practice
change policy based upon the results in an effort to improve patient safety. The
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results of the retrospective review were shared with the identified key
stakeholders in an effort to further reduce future incidence of adverse respiratory
events associated with residual neuromuscular blockade in the postoperative
patient.
Barriers
Some barriers this project encountered included time constraints, a limited
number of providers whom utilize Vecuronium as the neuromuscular blocking
agent of choice upon induction of anesthesia, the inability to discover an existing
data abstraction tool specific to this capstone project, and the limited number of
cases in which anesthesia providers re-dose paralytics.
Populations
A total of 50 subjects, 25 in each group, whom received either
Rocuronium or Vecuronium, were chosen for the retrospective analysis. The
inclusion population included any surgical patient ages 18-65 whom either
received an intubating dose or where re-dosed with the NMB agents Rocuronium
or Vecuronium during the procedure. Exclusion criteria included any surgical
patient ages 18-65 with ASA classification > 4, any emergent cases, any patient
whom only received a defaciculating dose of Rocuronium or Vecuronium, any
patient with documented neuromuscular disorder or history of prolonged
intubation, and patients arriving intubated preoperatively.
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Sampling
Since every retrospective chart review requires a statistical power analysis,
one was completed to determine the appropriate sample size. In addition,
convenience sampling, which is the most common method, was utilized. With
convenience sampling, the subjects included in the study are used because they
“happened to be in the right place at the right time” (Grove, Burns, & Gray, 2013,
p. 363). Of course, with this sampling, the researcher continued to enter subjects
into the study until the desired sample size was obtained.
To prevent bias during sampling and collection of data, the investigator
employed a specific procedure of review. First, each time the investigator audited
charts, a different month of surgical cases were reviewed. Upon entering the
health record for the first case, the gender was obtained and then the age. If the
patient was under the age of 18 or over the age of 65, the audit ceased. Next, the
ASA was viewed. If the ASA was greater than 4 or classified as an emergent
case, the audit ceased. If criteria were found appropriate, comorbidities, the
inhalation agent used, temperature, and BMI were recorded. Then the paralytic
agent was reviewed. If the patient was not intubated with the paralytic
Rocuronium or Vecuronium, or was not re-dosed with one of these agents, the
audit of this chart ceased. If criteria were found appropriate to this point, the total
doses of Rocuronium or Vecuronium, reversal, TOF, and all other variables found
on the data abstraction tool were recorded. Next, the investigator reviewed the
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first vital signs recorded in the PACU area after surgery. If an adverse respiratory
event was noted, the data received a yes in the adverse event category. If not, a
no was recorded. Data were collected until minimum of 25 charts were audited of
patients whom had received Rocuronium and 25 whom had received Vecuronium.
Lastly, to prevent bias, the investigator only included the data of the first 25
whom received Rocuronium regardless of the outcomes, and the first 25 of those
whom received Vecuronium, regardless of if an adverse event occurred.
Research Strategies
To explore the capstone question in the surgical patient requiring
neuromuscular blockade, is there an increased incidence of postoperative adverse
respiratory events with Rocuronium or Vecuronium a retrospective cohort study
was completed. A retrospective cohort study is a study in which the researcher
identifies a group of people (Rocuronium versus Vecuronium recipients) who
have experienced a particular event (adverse respiratory event). Therefore, a
retrospective analysis of de-identified electronic health record data was
performed. Inclusion criteria included all surgical patients whom received NMB
of Rocuronium or Vecuronium during the procedure. Exclusion criteria included
any surgical patient with ASA classification > 4, any emergent cases, any patient
with documented neuromuscular disorder or history or prolonged intubation, and
patients arriving to OR previously intubated.
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The study involved the collection of existing data from the electronic
medical record, and not any experimental procedures. Confidentiality of records
was maintained throughout the collection of data from the electronic health
record. The investigator in such a manner recorded all information that subjects
cannot be identified, directly or indirectly.
After data was analyzed, results were shared with key identified
stakeholders, and a white paper proposal was formulated. According to the
AANA (2014), a white paper is “complete descriptions of a particular concept,
position or solution to a problem, from overview to detailed facts, created to
promote professionalism and advocacy. Intended to guide decision-makers on
policy development” (p. 2). Therefore, as stated before, a white paper proposal
was formulated after all data was collected and reported in a manner in which the
subject were not and could not be identified.
Methods
After obtaining approval from the institutional review board (IRB) at the
university and the clinical site, the retrospective analysis began. A retrospective
analysis of de-identified electronic health record data was performed using a
medical record abstraction form. According to Banks (1998), a well-designed
data abstraction tool is designed to promote accuracy of data transcription, limit
the likelihood of missing data, and is designed to promote accurate data entry into
the computerized database for analysis. This investigator developed a data
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abstraction tool that included the variables of gender, age, ASA classification,
type of surgery, length of surgery, number of doses of each paralytic (total dose
administered), reversal (full, partial, or none), inhalation agent used during
procedure, TOF documentation, TOF documentation when reversed, temperature,
BMI, comorbidities, time of last dose of paralytic to reversal, time of last
dose/reversal to extubation time, narcotic used, dose of narcotic, and if adverse
event experienced.
Inclusion criteria included any surgical patients aged 18-65 receiving
NMB of Rocuronium or Vecuronium during the procedure. Exclusion criteria
included any surgical patient with ASA classification > 4, any emergent cases,
any patient with documented neuromuscular disorder or history or prolonged
intubation, and patients arriving intubated preoperatively. A Pearson’s ChiSquare Test was used to evaluate whether the patients receiving Rocuronium
experience a greater increase in post-operative adverse respiratory events
compared with the patients whom received Vecuronium.
Confidentiality of records was maintained throughout the collection of
data from the electronic health record, and the investigator recorded all data in
such a manner that subjects cannot be identified directly or indirectly. After data
was analyzed, a white paper proposal was formulated, and results were shared
with key identified stakeholders.
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Measurement Method
The measurement methodology for this capstone involved performing a
retrospective chart review analysis from computerized healthcare information at
the clinical site. According to Groves and colleagues (2013), data collected from
stored electronic healthcare information is considered secondary data, and these
databases provide large amounts of information relevant for research. In addition,
according to Gearing and colleagues (2006), data should be extracted effectively
and systematically. To begin, a literature review was performed to identify the
variables that could potentiate the problem of residual neuromuscular blockade.
After all variables were identified, a data extraction instrument was created (See
Appendix C).
According to Gearing et al. (2006), data collection should be organized to
follow the flow of the health care record. Each variable needs a simple and
definite response section, where the information can be captured. Internal validity
and reproducibility of any retrospective study is greatly enhanced if the data is
standardized (Jansen et al., 2005). Lastly, according to Allison et al. (2000), paper
or an electronic document can be the data abstraction instrument.
To begin, the anesthesia record was reviewed to determine the flow of
data in regards to the variables identified. Second, permission from the clinical
site was obtained to perform the retrospective analysis of the health records. It
was determined a paper document would be created and utilized during the chart
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reviews, and the information would be collected in such a manner that no subjects
could be identified. The abstractor guaranteed in writing to destroy the paper
document after all information had been analyzed. As stated before, each variable
needs a simple and definite response. The data extraction instrument was created
with the following legend: gender coded as M for male, F for female; age coded
with numeric number; ASA classification coded as I, II, III, or IV; comorbidities
coded R for respiratory issue, C for cardiac, N for neurological, H for hepatic, G
for gastrointestinal, R for renal, E for endocrine, O for other; inhalation agent
coded as S for sevoflurane, D for desflurane, I for isoflurane; temperature coded
with numerical number in Celsius; BMI coded with numerical number; paralytic
used coded as R for Rocuronium, V for Vecuronium; total dose of paralytic coded
in numerical number as dose in milligrams; reversal agent coded T for total, P for
partial dose, N for no reversal agent used; time of last dose to reversal coded in
numerical number in minutes; time of last dose/reversal dose to extubation coded
in numerical number in minutes; TOF documentation coded as Y for yes, N for
no; TOF documentation when reversed coded as numerical number; type of
procedure coded as A for abdominal, E for extrathoracic, O for orthopedic, H for
head; P for perineal, I for intrathoracic, N for neuroskeletal, S for spine, V for
vascular; length of surgery coded in numerical number in minutes; narcotic coded
F for fentanyl, M for morphine, D for dilaudid, P for precedex; narcotic dosage
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coded as numerical number in milligrams; and adverse event coded as Y for yes
or N for no.
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CHAPTER III
ANALYSIS OF DATA
The purpose of this capstone project was to perform a retrospective cohort
analysis utilizing a well-developed data abstraction tool to determine if surgical
patients requiring NMB were at greater risk of experiencing an adverse
respiratory event with Rocuronium or Vecuronium. The analysis of data is
organized as follows: 1) Statistical Analysis, 2) Presentation of Findings, and 3)
White Paper Change Proposal.
Statistical Analysis
After data was extracted into categorical variables, a Pearson’s chi-square
test using Statistical Package for the Social Sciences (SPSS) for association was
performed. With the chi-square test, it is utilized to determine if a relationship
exists between two categorical variables. According to Daniel (2009), the chisquare distribution is the most frequently used statistical tool for analysis of
frequency or count data. Furthermore, a hypothesis and null hypothesis was
developed. The hypothesis for the capstone was: there is an increased incidence
of adverse respiratory events with Rocuronium versus Vecuronium? The null
hypothesis was: there is not a significant increase incidence of adverse respiratory
events with Rocuronium over Vecuronium? Lastly, the level of significance was
computed. According to Daniel (2009), “the level of significance  is a
probability and, in fact, is the probability of rejecting a true null hypothesis” (p.
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220). As known in statistics, an alpha of 0.05 is the maximum level in scientific
research. Therefore, this capstone analyzed the data at the significance level of
0.05.
Presentation of Findings
The retrospective analysis was conducted at a level II regional trauma
center located in Hattiesburg, Mississippi over a four-month period. All surgical
patients who underwent general anesthesia and received either Rocuronium or
Vecuronium during the procedure were reviewed. A convenience sample of 50
subjects, 25 whom received Rocuronium and 25 whom received Vecuronium,
were chosen for the project. Inclusion criteria included any surgical patient ages
18-65 whom received the NMB agents Rocuronium or Vecuronium during the
procedure. Exclusion criteria included any surgical patient ages 18-65 with an
ASA classification > 4, any emergent cases, any patient with documented
neuromuscular disorder or history of prolonged intubation, and patients arriving
intubated preoperatively.
The retrospective analysis of de-identified electronic health record data
was performed using a paper medical record abstraction form. Demographic
characteristics of all patients were collected, and can be reviewed on Table 1.
Confidentiality of the information was maintained throughout the collection of
data, and the investigator recorded all data in such a manner that subjects cannot
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be identified directly or indirectly. The abstractor, as guaranteed in writing to
IRB, destroyed the paper document after all information was analyzed.
Table 1
Demographic Characteristics of All Patients

Characteristic

Number

Percentage

__________________________________________________________________
Gender
Male
Female

24
26

Age (y)
Mean
Range

52.5
18 – 65

Mean length surgery (min)

126

Body mass index (kg/m2)
Mean
Range

27.9
19.5 – 46.6

ASA category
I
II
III
IV

4
17
26
3

8
34
52
6

Type of surgery
Abdominal
Orthopedic

33
5

66
10

48
52

__________________________________________________________________
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Table 1 (continued).
__________________________________________________________________
Characteristic

Number

Percentage

__________________________________________________________________
Neurosurgery
Extrathoracic
Thyroid
Spine
Intrathoracic

3
2
3
3
1

6
4
6
6
2

__________________________________________________________________

Only 7 of the sample of patients experienced an adverse respiratory event.
Two of the patients were males, 5 were females, averaged 43 years of age (range,
27 to 65), and average BMI was 30.9 (range, 19.5 to 39 kg/m2), placing all but
one patient into the overweight or obese categories. Demographic characteristics
of these patients can be viewed in Table 2.
Table 2
Demographic Characteristics of Those Whom Experienced Adverse Event
_________________________________________________________________
Gender

ASA Paralytic Age Inhalation BMI Surgery Length of
Agent
Surgery (minutes)

_________________________________________________________________
Female

III

V

57

S

36.9

A

117

__________________________________________________________________
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Table 2 (continued).
__________________________________________________________________

Gender

ASA Paralytic Age Inhalation BMI Surgery Length of
Agent
Surgery (minutes)

__________________________________________________________________
Female

IV

V

65

S

19.5

A

153

Male

III

R

24

D

25.9

O

67

Female

II

R

27

D

35.3

A

182

Female

IV

R

62

S

32

N

84

Male

III

R

60

S

28

A

112

Female

III

R

44

S

39

T

141

__________________________________________________________________
Note. R = Rocuronium; V = Vecuronium; D = Desflurane; S = Sevoflurane; A = Abdominal; N = Neurosurgery; T =
Thyroid; O = Orthopedic; BMI – Body Mass Index

A Pearson chi-square test of independence was performed to examine the
relationship between the paralytic used and if an adverse respiratory event
occurred. Of the patients whom receive the NMB agent Rocuronium, 80% did
not experience an adverse respiratory event such as SpO2 < 90%, arrived to PACU
intubated, or had to be re-intubated in PACU, and 20% did experience an event
(Table 3). Of the patients whom received the NMB agent Vecuronium, 92% did
not experience an adverse respiratory event and 8% did experience an event.
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Although the differences in percentages appears large, the relationship, as seen in
Table 4, between these variables were found to be insignificant, (N=50, df=1) =
1.495, p = 0.221.
Table 3
Adverse Event and Paralytic Crosstabulation
_________________________________________________________________
Paralytic
R

V

Total

_________________________________________________________________
Adverse Event

N

Y

Total

Count

20

23

43

% within paralytic

80.0%

92.0%

86.0%

Count

5

2

7

% within paralytic

20.0%

8.0%

14.0%

Count

25

25

50

100.0%

100.0%

% within paralytic 100.0%

_________________________________________________________________
Note. R = Rocuronium; V = Vecuronium; N = No; Y = Yes.
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Table 4
Pearson’s Chi-Square test table for Adverse Event and Paralytic
__________________________________________________________________
Value

df

Asymptotic Sig. (2-sided)

__________________________________________________________________

Pearson Chi-Square

1.498a

1

.221

Continuity Correctionb

.664

1

.415

__________________________________________________________________
Note. df = Degree of freedom; a = 2 cells (50%) have expected count less than 5; b = Computed only for a 2 x 2 table.

Although the project did not provide a statistically significant relationship
between adverse respiratory events and the usage of Rocuronium or Vecuronium,
some serendipitous findings were noted. One serendipitous finding throughout
this project was the significant relationship found between the variables of
adverse events and the usage of NMB reversal agent (Table 5).
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Table 5
Reversal and Adverse Event Crosstabultion
___________________________________________________________________________________________________

Reversal

Adverse Event
N

Total
Y

__________________________________________________________________
None

Partial

Complete

Totals

Count

8

5

13

% within

18.6%

71.4%

26.0%

Count

15

1

16

% within

34.9%

14.3%

32.0%

Count

20

1

21

% within

46.5%

14.3%

42.0%

Count

43

7

50

% within

100.0%

100.0%

100.0%

__________________________________________________________________
Note. N = No; Y = yes.

A Pearson’s chi-square test revealed (N=50, df=1) = 8.747, p = 0.013
(Table 6). Of the 7 patients whom experienced an adverse respiratory event
postoperatively, 5 did not receive a NMB reversal agent, 1 received a partial
dosage, and 1 received a total reversal dose. However, it was of interest that the
patient whom received total reversal, that patient had been re-dosed 16 minutes
prior with Vecuronium. As literature states, Vecuronium has a half-life of 51 to
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91 minutes and duration of 30 to 45 minutes. Therefore, it is probable the
reversal dose may have potentiated the NMB thus leading to the adverse
respiratory event.
Table 6
Pearson Chi-Square test table for Reversal and Adverse Event
__________________________________________________________________
Value

df

Asymptotic Sig. (2-sided)

__________________________________________________________________
Pearson Chi-Square

8.747a

2

.013

Likelihood Ratio

7.651

2

.022

Number of Valid Cases

50

__________________________________________________________________
Note. df = Degree of Freedom; Sig = Significance; a = 3 cells (50%) have expected count less than 5. The minimum
expected count is 1.82.

Another serendipitous finding was that 100% of the patients whom
experienced an adverse respiratory event had not received TOF evaluation during
nor prior to extubation. Table 7 compares the variables of measuring TOF to
adverse events. Although this finding had a p value of .075 and is therefore
considered insignificant, it is hypothesized that a larger data sampling may allow
the variable to become statistically significant (Table 8).
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Table 7
TOF and Adverse Event Crosstabulation
__________________________________________________________________
TOF

Adverse Event
N

Total
Y

__________________________________________________________________
TOF

N Count

29

7

36

% within

67.4%

100.0%

72.0%

Y Count

14

0

14

% within

32.6%

0.0%

28.0%

_________________________________________________________________
Note. N = no; Y = yes.

Table 8
Pearson’s Chi-Square test table for TOF and Adverse Event
__________________________________________________________________
Value

df

Asymptotic Sig. (2-sided)

__________________________________________________________________
Pearson Chi-Square
Likelihood Ratio

3.165a

1

.075
.025

__________________________________________________________________
Note. df = Degree of Freedom; Sig = Significance; a = 1 cells (25.0%) have expected count less than 5. The minimum
expected count is 1.96.
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White Paper Change Proposal
The desired goal for this capstone project was to determine if surgical
patients requiring NMB agents were at greater risk of experiencing an adverse
respiratory event with the intermediate acting agents Rocuronium or Vecuronium.
The desired outcome was to develop a white paper practice change proposal based
upon the results in an effort to improve patient safety. According to the AANA
(2014), a white paper is “complete descriptions of a particular concept, position or
solution to a problem, from overview to detailed facts, created to promote
professionalism and advocacy. Intended to guide decision-makers on policy
development” (AANA, 2014, p. 1). Although no statistically significant
relationship was found between the variables of adverse events and the paralytics
Rocuronium or Vecuronium, unanticipated findings did occur. The serendipitous
results regarding the variable of the usage of a reversal agent and possibly usage
of TOF monitoring did provide positive findings for areas of improvement. The
results of this capstone was shared with identified key stakeholders at the hospital
in which the retrospective analysis occurred in an effort to further reduce future
incidence of adverse respiratory events associated with residual neuromuscular
blockade in the postoperative patient.
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CHAPTER IV
SUMMARY
The purpose of this capstone project was to perform a retrospective cohort
analysis utilizing a well-developed data abstraction tool to determine if surgical
patients requiring NMB were at greater risk of experiencing an adverse
respiratory event with Rocuronium or Vecuronium. This chapter is organized as
follows: 1) Summary of Findings, 2) Recommendations, and 3) Conclusions.
Summary of Findings
The major finding of the project included there is no statistically
significant relationship between increased incidences of postoperative adverse
respiratory events with the usage of Rocuronium over Vecuronium. However, the
project did provide a statistically significant relationship between adverse
relationships and patients not being fully reversed from the NMB agent. This
finding correlates with the recommendation that routine pharmacologic reversal
of a nondepolarizing NMB should occur. Furthermore, the project determined
that TOF monitoring is only occurring 28.0% of the time even though this is
considered an AANA Standard. According to the AANA Standards for Nurse
Anesthesia Practice (2013), the standard is as follows: “when neuromuscular
blocking agents are administered, monitor neuromuscular response to assess depth
of blockade and degree of recovery” (p. 2). Therefore, to adequately monitor the
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depth of blockade and degree of recovery, the anesthesia provider should utilize
certain techniques such as physical assessment and TOF monitoring.
Recommendations
Given the relatively small sample size and short duration of the
retrospective analysis, it is recommended the proposed changes made with the
white paper proposal be tested to verify feasibility and accuracy of the proposed
changes. Each variable previously reviewed could be reevaluated in an effort to
determine if practice changes have decrease the incidence of adverse respiratory
events associated with residual NMB.
Conclusion
The findings of this retrospective analysis may not have proven the
hypothesis that Rocuronium is associated with increased risks of postoperative
adverse respiratory events. However, this capstone was instrumental in providing
a statistically significant relationship between the usage of reversal agents and the
incidence of adverse respiratory events. Residual neuromuscular blockade is not a
new phenomenon. It is hopeful that this capstone has provided the key
stakeholders current evidence-based knowledge regarding the neuromuscular
blocking agents Rocuronium and Vecuronium, the recommended practice of
reversal, and the knowledge that TOF monitoring is now considered an AANA
and ASA standard of care.
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APPENDIX A
FORREST GENERAL IRB APPROVAL LETTER
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APPENDIX B
UNIVERSITY OF SOUTHERN MISSISSIPPI IRB APPROVAL LETTER
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APPENDIX C
DATA COLLECTION TOOL
Adverse Event

Narcotic Dose

Narcotic

Surgery Length

Surgery

TOF when reversed

TOF

Time last does/reversal to extubation

Time Last dose of reversal

Reversal

Paralytic total dose

Paralytic Agent

BMI

Temperature

Inhalation Agent

Comorbidities

ASA

Age

Gender

Legend
Gender
Age
ASA
Comorbidities

Inhalation agent
Temperature
BMI
Paralytic agent
Total dose of paralytic
Reversal Agent
Time last dose of reversal
Time last dose/reversal to extubation
TOF
Type of procedure

Length of surgery
Narcotic
Narcotic dose
Adverse event

M = male; F = female
Numerical number expressed in years
I, II, III, IV
R = respiratory; C = cardiac; N = neurological;
H = hepatic; G = gastric;
R = renal; E = endocrine; O = other
S = Sevoflurane; D = Desflurane; I = Isoflurane
Numerical number in Celsius
Numerical number
R = Rocuronium; V = Vecuronium
Numerical number expressed in milligrams
T = total; P = partial; N = no reversal used
Numerical number in minutes
Numerical number in minutes
Numerical number
A = abdominal; E = extrathoracic; O =
orthopedic; H = head; P = perinal; I =
intrathoracic; N = neuroskeletal; S = spine; V =
vascular
Numerical number in minutes
F = fentanyl
Numerical number in micrograms
Y = yes; N = no
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